Di Colo Giacomo, Zambito Ylenia, Zaino Chiara
Department of Bioorganic Chemistry and Biopharmaceutics, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy.
J Pharm Sci. 2008 May;97(5):1652-80. doi: 10.1002/jps.21043.
Transmucosal drug administration across nasal, buccal, and ocular mucosae is noninvasive, eliminates hepatic first-pass metabolism and harsh environmental conditions, allows rapid onset, and further, mucosal surfaces are readily accessible. Generally, however, hydrophilic drugs, such as peptides and proteins, are poorly permeable across the epithelium, which results in insufficient bioavailability. Therefore, reversible modifications of epithelial barrier structure by permeation enhancers are required. Low molecular weight enhancers generally have physicochemical characteristics favoring their own absorption, whereas polymeric enhancers are not absorbed, and this minimizes the risk of systemic toxicity. The above considerations have warranted the present survey of the studies on polymeric transmucosal penetration-enhancers that have appeared in the literature during the last decade. Studies on intestinal permeation enhancers are also reviewed as they give information on the mechanism of action and safety of polymers. The synthesis and characterization of polymers, their effectiveness in enhancing the absorption of different drugs across different epithelium types, their mechanism of action and structure-efficacy relationship, and the relevant safety issues are reviewed. The active polymers are classified into: polycations (chitosan and its quaternary ammonium derivatives, poly-L-arginine (poly-L-Arg), aminated gelatin), polyanions (N-carboxymethyl chitosan, poly(acrylic acid)), and thiolated polymers (carboxymethyl cellulose-cysteine, polycarbophil (PCP)-cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, chitosan-glutathione conjugates).
经鼻、颊和眼黏膜进行的透黏膜给药是非侵入性的,可消除肝脏首过代谢以及恶劣的环境条件,起效迅速,而且黏膜表面易于触及。然而,一般来说,亲水性药物,如肽和蛋白质,很难透过上皮细胞,这导致生物利用度不足。因此,需要用渗透促进剂对上皮屏障结构进行可逆修饰。低分子量促进剂通常具有有利于自身吸收的物理化学特性,而聚合物促进剂不会被吸收,这将全身毒性风险降至最低。基于上述考虑,有必要对过去十年文献中出现的聚合物透黏膜渗透促进剂的研究进行本次综述。对肠道渗透促进剂的研究也进行了综述,因为它们提供了有关聚合物作用机制和安全性的信息。本文综述了聚合物的合成与表征、它们在促进不同药物跨不同上皮类型吸收方面的有效性、它们的作用机制和构效关系以及相关的安全问题。活性聚合物分为:聚阳离子(壳聚糖及其季铵衍生物、聚-L-精氨酸(聚-L-Arg)、胺化明胶)、聚阴离子(N-羧甲基壳聚糖、聚丙烯酸)和硫醇化聚合物(羧甲基纤维素-半胱氨酸、聚卡波非(PCP)-半胱氨酸、壳聚糖-硫代丁脒、壳聚糖-巯基乙酸、壳聚糖-谷胱甘肽缀合物)。